IMR Press / FBL / Volume 16 / Issue 7 / DOI: 10.2741/3884

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Alternative splicing of RAGE: roles in biology and disease
Show Less
1 Division of Nephrology/Hypertension, Feinberg School of Medicine, Northwestern University, IL, USA
2 Department of Medicine and Pharmacology, NYU Langone Medical Center, NY, USA
3 Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, FL, USA
Academic Editor:Li Lin
Front. Biosci. (Landmark Ed) 2011, 16(7), 2756–2770;
Published: 1 June 2011
(This article belongs to the Special Issue RAGE signaling)

The Receptor for Advanced Glycation End-products (RAGE) is a complex, multi-ligand signaling system implicated in the pathogenesis of diabetes, cardiovascular disease and various cancers. RAGE undergoes extensive alternative splicing to produce a variety of transcripts with diverse functions, including soluble antagonists and variants with altered ligand binding domains. Studies focused on the major soluble variant (RAGEv1/esRAGE) have revealed this to function by binding RAGE-ligands and preventing activation of RAGE signaling in vascular and tumor cells. Furthermore, measurement of this variant in human serum has revealed that RAGEv1/esRAGE levels may represent a novel biomarker for RAGE-ligand related pathogenic states. Understanding the full plethora of RAGE alternative splicing and its regulation is central to elucidating the role of RAGE in biology and disease.

Back to top